Nectar Lifesciences (LUX:NECLF) ROCE % : 11.58% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nectar Lifesciences's annualized ROCE % for the quarter that ended in Mar. 2024 was 11.58%.

Nectar Lifesciences ROCE % Historical Data

The historical data trend for Nectar Lifesciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences ROCE % Chart

Nectar Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

8.94

0.08

7.87

2.65

8.34

Nectar Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															6.51	6.37	7.05	8.66	11.58

Nectar Lifesciences ROCE % Calculation

Nectar Lifesciences's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	12.697	/	( ( (266.112 - 108.298)	+	(263.915 - 117.177) )	/ 2 )
	=	12.697	/	( (157.814	+	146.738)	/ 2 )
	=	12.697	/	152.276
	=	8.34 %

Nectar Lifesciences's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	16.996	/	( ( (0 - 0)	+	(263.915 - 117.177) )	/ 1 )
	=	16.996	/	( ( 0	+	146.738 )	/ 1 )
	=	16.996	/	146.738
	=	11.58 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Nectar Lifesciences (LUX:NECLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nectar Lifesciences ROCE % Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nectar Lifesciences (LUX:NECLF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » ROCE %

Traded in Other Exchanges

NECLIFE:India 532649:India

Address

SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009

Website

https://www.neclife.com

Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines